The underestimated risk of
|
|
- Maude Gardner
- 6 years ago
- Views:
Transcription
1 Earn 3 CPD Points online The underestimated risk of hypertension Dr David Webb Johannesburg Introduction The high and increasing worldwide burden of hypertension is a major global health challenge. Hypertension increases morbidity and mortality from cardiovascular (CV) and kidney diseases and is responsible for significant financial costs to society. Ischaemic heart disease and stroke, a substantial proportion of which is attributable to hypertension, are the leading causes of death worldwide, accounting for approximately one in four deaths. Most people with clinical hypertension have additional CV risks and/or evidence of blood pressure-related damage (heart disease, stroke and kidney damage). Without effective early intervention to improve blood pressure control, the global epidemic of CV and kidney disease is expected to continue to increase, especially in low- and middle-income countries. 1,2 KEY MESSAGES Only one in five South Africans diagnosed with and treated for hypertension is under control Women are more aware of hypertension as a health problem and are twice as likely as men to seek treatment The greatest success achieved with blood pressure lowering is seen in patients with lowmoderate risk before hypertensive organ damage occurs Intervene earlier and avoid progression to high risk More intense blood pressure reduction is associated with a significantly lower risk of stroke (29%) A recent meta-analysis of more than patients showed the relative strengths of different classes of antihypertensive agents that can help to guide choice of therapy This report was made possible by an unrestricted educational grant from Zentiva/Sanofi. The content of the report is independent of the sponsor. Clinical studies support the use of combination therapy with either an angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB), plus either a diuretic and/or calcium channel blocker (CCB) as rational first-line and second-line therapy. Prevalence of hypertension In 2010, the estimated global agestandardised prevalence of hypertension in adults aged 20 years was approximately 30%. Approximately three-quarters of hypertensive individuals live in low- and middle-income countries, where the number of adults with hypertension (1.04 billion) is almost three times that in high-income countries (349 million). In low-, middle- and high-income countries, hypertension prevalence increases with age (Table 1). Between the years 2000 and 2010, the overall global prevalence of hypertension increased by 5.2%. However, the prevalence in high-income countries decreased by 2.6%, whereas in low- and middleincome countries it increased by 7.7%. 1 january
2 Table 1. Prevalence of hypertension in Age (years) High-income countries Low- and middle-income countries Men (%) Women (%) Men (%) Women (%) Overall Hypertension awareness, treatment and blood pressure control Worldwide, less than half of hypertensive adults are aware of their condition. Although the majority of those who are aware of their hypertension are receiving treatment, blood pressure control rates are poor, with fewer than one in six controlled to acceptable levels. In comparison with high-income countries, awareness, treatment and control are all substantially lower in low- and middleincome countries, including South Africa (Tables 2 and 3). 1,3 Table 2. Proportions of awareness, treatment and blood pressure control in Region Awareness Treatment Control High-income countries 67.0% 55.6% 28.4% Low- /middle-income countries 37.9% 29.0% 7.7% Table 3. Gender-specific hypertension awareness, treatment and control in 2010 in South Africa 1 Awareness Treatment Control (among treated) Control (among those with hypertension) Men Women Men Women Men Women Men Women Impact of hypertension Hypertension is the leading risk factor for death and disability globally. 4 It is responsible for 50% of heart disease, stroke and heart failure. Overall, hypertension accounts for 18% of all deaths and for more than 40% of deaths among people with diabetes. It is the leading risk for foetal and maternal death in pregnancy and also for death among those with dementia or renal failure. 2 In people aged 30 years, hypertension (blood pressure 140/90mmHg or receiving blood pressure-lowering medication) is associated with an overall lifetime risk of CV disease of 63%, compared with 46% for those with a normal blood pressure; hypertensive individuals tend to develop CV disease on average five years earlier. 5 2 january 2018
3 Effect of hypertension treatment on CV outcomes Meta-analyses of randomised controlled clinical studies of antihypertensive treatment indicate that reducing blood pressure in hypertensive individuals significantly reduces the risk of CV outcomes, CV-related deaths and all-cause mortality (Table 4). For every 1000 people treated with antihypertensive therapy for five years, an average blood pressure reduction of 10/5mmHg would prevent 28 cardiovascular events. 6 Although greater blood pressure reductions are associated with greater risk reduction, the relationship is not proportional or linear. Progressively lower reduction results in progressively lower increments in risk reduction. 6,7 Table 4. Relative and absolute risk reduction of various outcomes in blood pressurelowering trials. Standardised risk reduction is to a SBP/DBP reduction of 10/5mmHg Outcome Relative risk reduction Absolute risk reduction (per 1000 patients treated for five years) Number needed to treat Stroke 36% Coronary heart disease 16% Heart failure 43% CV events* 25% CV death 18% All-cause death 11% SBP: systolic blood pressure; DBP: diastolic blood pressure *Composite of stroke, coronary heart disease and heart failure All grades of hypertension are similarly susceptible to the beneficial effects of blood pressure lowering. Consequently, antihypertensive treatment should be considered for all adult individuals whose blood pressure values remain 140/90mmHg, despite adequate lifestyle interventions. Furthermore, recognising the benefit of treating blood pressure in patients with grade 1 hypertension is important, because the majority of those seeking counselling about drug treatment initiation fall into this group and their total CV risk is usually considered to be low to moderate (risk of CV death <5% in 10 years). 7 Antihypertensive therapy and residual risk Relative risk reduction for CV events with antihypertensive therapy is fairly constant, regardless of the level of baseline blood pressure and baseline risk. Accordingly, absolute risk reductions increase significantly with increasing level of baseline CV risk (Table 5). However, with higher baseline risk, the residual risk remaining after initiation of antihypertensive treatment will also be greater. Consequently, if the success of antihypertensive therapy is measured not only by prevention of CV events (risk reduction), but also by absolute level of treatment failures (residual risk), then it is clear that the greatest success of blood pressure lowering is achieved in patients with low-moderate risk, before hypertensive organ damage occurs (only 34 instead of 218 major CV events occurring per 1000 patients treated for five years). 7,8 january
4 Table 5. Absolute risk reduction and residual risk in blood pressure-lowering trials according to baseline CV risk (for composite of stroke, coronary heart disease or heart failure). Standardised risk reduction is to a SBP/DBP reduction of 10/5mmHg 8 Baseline CV risk Absolute risk reduction/nnt (per 1000 patients treated for five years) Residual risk (per 1000 patients treated for five years) Odds ratio (95% CI) vs low-moderate baseline risk Low-moderate risk (<5%) High risk (5% to <10%) Very high risk (10% to <20%) Very, very high risk ( 20%) -7 NNT = NNT = NNT = NNT = ( ) ( ) ( ) How can residual risk be reduced? Intervene earlier and avoid progression to high risk In addition to hypertension, major contributors to global mortality include tobacco smoking (including second-hand smoke), a diet low in fruit and vegetables and high in sodium, high body mass index, physical inactivity and high fasting plasma glucose. 4 Educating and assisting the population in general remains paramount in helping people to maintain a More intense blood pressure reduction (lower target) healthy body weight, physical activity and healthy nutrition as they get older. As discussed above, where pharmacological intervention is necessary, starting treatment earlier when baseline risk is still lower, rather than later, may yield significantly greater returns in terms of CV disease reduction. In a meta-analysis of randomised controlled clinical trials published between 1966 and 2015, more intense blood pressure lowering was associated with a significantly lower risk of stroke (29%), coronary events (20%), major CV events (25%) and CV mortality (21%), but not heart failure or all-cause death. Considering three levels of target systolic blood pressure (150mmHg, 140mmHg and 130mmHg), reducing blood pressure with a difference of -10/-5mmHg across each cut-off yielded a similar relative risk reduction, but a lower absolute risk reduction at the lower cut-offs (due to a progressively lower level of baseline risk; Table 6). 9,10 Table 6. Relative and absolute risk reduction of CV events (composite of stroke, coronary heart disease and heart failure) in blood pressure-lowering trials. Standardised risk reduction is to a SBP/DBP reduction of 10/5mmHg 10 Blood pressure cut-off (mmhg) Relative risk reduction Absolute risk reduction (per 1000 patients treated for five years) NNT vs vs <130 vs january 2018
5 Does the type of initial antihypertensive therapy matter? In meta-analyses of 55 eligible randomised clinical trials comparing different antihypertensive monotherapies and including more than patients and more than one million patient years, all antihypertensive drug classes were associated with similar positive outcomes (reduction in stroke and major CV events) when blood pressure-lowering efficacy was equivalent. 11 However, when compared to all other classes together, there were some differences noted for each of the monotherapy classes, which might be important when considering antihypertensive therapy for specific individual patients: Diuretics were superior in preventing heart failure; Beta-blockers were less effective in preventing stroke; Calcium channel blockers (CCBs) were superior in preventing stroke and all-cause death, but inferior in preventing heart failure; Angiotensin-converting enzyme inhibitors (ACE-inhibitors) were more effective in preventing coronary heart disease and less effective in preventing stroke; Angiotensin receptor blockers (ARBs) were less effective at preventing coronary heart disease; Renin-angiotensin system blockers (ACE-inhibitors and ARBs) were more effective in preventing heart failure; Baseline CV risk had no effect on the effectiveness of any drug class. The meta-analysis confirms guideline recommendations that the main goal of antihypertensive treatment is blood pressure lowering with the aim of achieving and maintaining a specific goal blood pressure. Choice of antihypertensive treatment should be individualised according to response to the individual agent and tolerability. If it is suspected that the patient may be at higher risk of a specific CV outcome, then the observations above might help to direct therapy. Similarly, possible differences in the effects of the various antihypertensive classes on onset and progression of organ damage may also be taken into account. Combination therapy The majority of hypertensive patients need two or more antihypertensive agents to reach blood pressure targets. As an estimate, one-third may be successfully treated with monotherapy, one-third may require two and the remaining one-third of patients will need three or more antihypertensive agents for effective blood pressure control. 12 When monotherapy fails to control blood pressure, switching to another antihypertensive (sequential monotherapy) or serially increasing the dose of the initial antihypertensive drug is no longer recommended, since patients who fail a trial of monotherapy are more likely to respond to a combination of low-dose antihypertensive drugs. When combination therapy is required then two drugs should be selected that have both complementary mechanisms of action and, if possible, complementary effects on different CV outcomes. Table 7. Recommended combination therapy for patients with hypertension A: ACE-inhibitor or ARB; C: CCB; D: thiazide-type diuretic Younger patients (<60 years of age) Older and black patients Proportion of patients controlled on therapy Step 1 A C or D 20-25% Step 2 A + C or A + D 60% Step 3 A + C + D 80-90% Step 4 Step 5 Add aldosterone antagonist Add alpha-blocker, beta-blocker, investigate for secondary causes, refer january
6 Table 7 lists combination antihypertensive therapies that are recommended based on results from clinical trials. Clinical studies support the use of an ACE-inhibitor or ARB plus either a diuretic and/or CCB as rational initial and second-line choices for combination therapy. Both diuretic and CCB combinations have been shown to reduce the incidence of CV morbidity and mortality in primary and secondary prevention studies in comparison with monotherapy and alternative combinations In contrast, combining an ACE-inhibitor with an ARB conferred no benefit in comparison to ACE-inhibitor or ARB monotherapy, but was associated with an increase in adverse effects. 26 Hypertension that is resistant to treatment with three or more blood pressure-lowering medications is estimated to occur in approximately 10% of treated hypertensive patients and is associated with a poor prognosis. On the basis that treatment resistance might be explained by sodium retention, the PATHWAY-2 study compared spironolactone (a mineralocorticoid receptor-blocking agent) with alternative fourth-line treatments (alpha- 1-adrenoceptor blocker, doxazosin and the beta-1-adrenoceptor blocker, bisoprolol) as add-on therapy in patients with uncontrolled blood pressure on triple therapy with an ACE-inhibitor or ARB plus a CCB and diuretic. Spironolactone was the most effective treatment and was well tolerated, with a low rate of adverse events and withdrawals due to adverse events. 16 Statin therapy The ASCOT-LLA study compared antihypertensive treatment with or without atorvastatin in patients with a baseline total cholesterol level of 6.5mmol/l. It was stopped prematurely after a median of 3.3 years follow-up because of substantial CV benefits in the group of patients assigned to atorvastatin. After both two years and 11 years follow-up, the benefits of early introduction of the statin remained, even among those who Conclusions Hypertension and other modifiable risk factors for CV disease remain a significant and urgent cause for concern the world over. Many of these risk factors are related to lifestyle and it is not uncommon for individuals to already have multiple risk factors when they first consult their doctor, and when the opportunity for early intervention has already been missed. Addressing CV risk once it has escalated to moderate or high risk, even with the most effective treatments, leaves a residual risk that far exceeds had discontinued statin therapy Similarly, low-dose rosuvastatin significantly reduced the risk of CV events in an ethnically diverse population without CV disease, but with at least one CV risk factor. In comparison with placebo, the composite endpoint of CV death, nonfatal myocardial infarction or nonfatal stroke was reduced by 24% among patients receiving rosuvastatin, regardless of baseline blood pressure levels. 31 that associated with untreated lower risk levels. Therefore, preventing CV disease starts with education and urging people to adhere to a healthier lifestyle in terms of physical activity and nutrition. Use of aggressive pharmacotherapy, for example combination antihypertensive treatment combined with other appropriate medication such as statins, should be borne in mind when making early treatment decisions, when the benefits are greater and more sustained than if it is left until later or used as a last resort. 6 january 2018
7 References 1. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control. A systematic analysis of population-based studies from 90 countries. Circulation 2016; 134: Campbell NRC, Lackland PH, Niebylski ML, et al. High blood pressure: why prevention and control are urgent and important - A 2014 Fact Sheet from the World Hypertension League and the International Society of Hypertension. J Clin Hypertens 2014; 16(8): Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and lowincome countries. JAMA 2013; 310(9): Lim S, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, : a systematic analysis for the Global Burden of Disease Study Lancet 2012; 380(9859): Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014; 383: Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses and metaregression analyses of randomized trials. J Hypertens 2014; 32: Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension. A critical reappraisal. Circ Res 2015; 116: Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 3. Effects in patients at different levels of cardiovascular risk. Overview and meta-analyses of randomized trials. J Hypertens 2014; 32: Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels updated overview and meta-analyses of randomized trials. J Hypertens 2016; 34(4): Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 2. Effects at different baseline and achieved blood pressure levels. Overview and metaanalyses of randomized trials. J Hypertens 2014; 32: Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015; 33: Düsing R. Optimising blood pressure control through the use of fixed combinations. Vasc Health Risk Manage 2010; 6: Seedat YK, Rayner BL, Veriava Y. South African Hypertension Practice Guideline Cardiovasc J S Afr 2014; 25(6): James PA, Oparil S, Carter BL, et al Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): Mancia G, Fagard R, Narkiewicz K, et al ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): PROGRESS Collaborative Group. Randomised trial of a perindopril based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus. Results from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertens 2014; 63: Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: Beckett N, Peters R, Leonetti G, et al. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens 2014; 32(7): Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: january
8 25. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: Sever PS, Dahlof B, Poulter NR, et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): multicentre randomised controlled trial. Lancet 2003; 361: Sever PS, Poulter NR, Dahlof B, et al. The Anglo- Scandinavian Cardiac Outcomes Trial lipid-lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008; 29(4): Holdaas H. Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better? Eur Heart J 2008; 29(4): Sever PS, Chang CL, Gupta AK, et al. The Anglo- Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J 2011; 32: Yusuf S, Bosch J, Zhu J, et al. Cholesterol-lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374: This article was written for DeNovo Medica by Dr David Webb, based on a presentation by Professor JA Ker at a cardiovascular risk meeting held at Three Rivers Lodge, Vereeniging. Earn CPD points online Visit Log in or register and start earning CPD points today. Certificates will be ed to you. Disclaimer The views and opinions expressed in the article are those of the presenters and do not necessarily reflect those of the publisher or its sponsor. In all clinical instances, medical practitioners are referred to the product insert documentation as approved by relevant control authorities. Published by 70 Arlington Street, Everglen, Cape Town, 7550 Tel: (021) I info@denovomedica.com 8 january 2018
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationWhen should blood pressure be lowered? Should treatment be guided by blood pressure values or total cardiovascular risk?
OF JOURNAL HYPERTENSION JH R RESEARCH Journal of HYPERTENSION RESEARCH www.hypertens.org/jhr Editorial J Hypertens Res (2016) 2(2):47 51 When should blood pressure be lowered? Should treatment be guided
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More informationHypertension is the most important cause of death globally, while the
CARDIOMETABOLIC DISEASE Earn 3 CPD Points online This article was made possible by an unrestricted educational grant by Servier Laboratories. New approaches to cardiometabolic disease Hypertension is the
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationEFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION
EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationHypertension in the elderly
091 Hypertension in the elderly Hypertension remains widely prevalent and a significant determinant of cardiovascular risk in the elderly population. Several large controlled trials have shown the benefits
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationAlberto Zanchetti 1 Costas Thomopoulos 2
Eπίκαιρο Άρθρο Which Drugs for Hypertension in 2017? Alberto Zanchetti 1 Costas Thomopoulos 2 ABSTRACT There are a number of different classes of blood pressure lowering drugs that have been widely used
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationLowering blood pressure in 2003
UPDATE CLINICAL UPDATE Lowering blood pressure in 2003 John P Chalmers and Leonard F Arnolda Institute for International Health, University of Sydney, Sydney, NSW. John P Chalmers, MD, FRACP, Professor
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More informationThe State of Hypertension in NZ in 2010 personal view
The State of Hypertension in NZ in 2010 personal view Patient referred to medical clinic Dear Dr, Please see this man with resistant hypertension 50 year old European male Blood Pressure on current meds
More informationComparative review of NICE, JNC8, SAHS and ISHIB. Brian Rayner, Division of Hypertension, University of Cape Town
Comparative review of NICE, JNC8, SAHS and ISHIB Brian Rayner, Division of Hypertension, University of Cape Town Scope of Problem Deaths attributable to high blood pressure in males, South Africa 2000
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationClinical cases with Coversyl 10 mg
Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationImpact of recent landmark clinical trials on hypertension treatment
Review: Clinical Trial Outcomes Impact of recent landmark clinical trials on hypertension treatment Clin. Invest. (2011) 1(8), 1141 1154 High blood pressure remains an important global cause of cardiovascular
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationChoice of therapy in esse... http://www.uptodate.co... Page 1 of 28 Official reprint from UpToDate www.uptodate.com Print Back Choice of therapy in essential hypertension: Recommendations Authors Norman
More informationΣυμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)
Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3) Χάρης Γράσσος MD,FESC,PhD,EHS Διευθυντής Καρδιολόγος Γ.Ν.Α ΚΑΤ Visiting Professor University of Bolton U.K New England
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationBLOOD PRESSURE-LOWERING TREATMENT
BLOOD PRESSURE-LOWERING TRIALS NUMBER OF PARTICIPANTS NUMBER OF PERCENTAGE OF MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 69,473 28,008 40.3% 70.2 3.2 3/5 (60%) APPENDIX 2 1 BLOOD PRESSURE-LOWERING
More informationManaging hypertension: a question of STRATHE
(2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,
More informationDon t let the pressure get to you:
Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular
More information2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines
Hypertension: 214 Highlights of Hypertension Guidelines: Making the Most of Limited Evidence Michael A, Weber, MD Editor-in-Chief, The Journal of Clinical Hypertension, Professor of Medicine, Division
More information47 Hypertension in Elderly
47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationAmlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy
ORIGINAL ARTICLE Korean J Intern Med 2014;29:315-324 and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy Seung-Ah Lee 1,
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationWill the recent hypertension trials change the guidelines?
710891JRA0010.1177/1470320317710891Journal of the Renin-Angiotensin-Aldosterone SystemSever research-article2017 Commentary Will the recent hypertension trials change the guidelines? Journal of the Renin-Angiotensin-
More informationTalking about blood pressure
Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight
More informationCauses of Poor BP control Rates
Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationRationale for the use of Single Pill Combination. Yong Jin Kim, MD Seoul National University Hospital
Rationale for the use of Single Pill Combination Yong Jin Kim, MD Seoul National University Hospital Unmet Need of Hypertension Treatment Hypertension # 1 Risk Factor for Global Mortality 0 1 2 3 4 5 6
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationDr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.
Dr Diana R Holdright MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION www.drholdright.co.uk Blood pressure is the pressure exerted on the walls of the arteries when the heart pumps;
More informationAbbreviations Cardiology I
Cardiology I and Clinical Controversies Joseph J. Saseen, Pharm.D., FCCP, BCPS (AQ Cardiology) Reviewed by Stuart T. Haines, Pharm.D., FCCP, BCPS; and Michelle M. Richardson, Pharm.D., FCCP, BCPS Learning
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationAntihypertensive Combinations
This Professional Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2016 ~ Resource #321047 Antihypertensive Combinations
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationBlood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension
525 Blood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension PHIMDA Kriangsak 1* and CHOTNOPARATPAT Paiboon 2 1 Diabetes and Hypertension Clinic,
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationManagement of Difficult or Resistant Hypertension in General Practice
Management of Difficult or Resistant Hypertension in General Practice JNC 7 Guidelines (2003) Classification of Blood Pressure Category SBP DBP Normal < 120 or < 80 Prehypertension 120-139 or 80-89 Stage
More informationHealthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice
CONTINUING EDUCATION Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice GOAL To provide participants with current information about current blood pressure goals and effective
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationExplore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management
Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr
More informationHypertension Guidelines: International; African,?Kenyan
Hypertension Guidelines: International; African,?Kenyan Elijah N. Ogola University of Nairobi Kenya Cardiac Society Symposium 24 th 25 th February 2017 Eldoret Outline Background Overview of international
More informationEvolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)
Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina
More informationDRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU
Original Article DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU V.Gowri 1, K.Punnagai, K.Vijaybabu 3, Dr.Darling Chellathai 4 1 Assistant Professor
More informationRationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC
Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC Seung Woo Park, MD Samsung Medical Center BP Control Rates in Asia BP controlled BP uncontrolled 24.3% 36.6% 19% Turkey
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationA fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a noninvestigational
Hostalek U et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 11 RESEARCH ARTICLE A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension:
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationThe JNC 8 Guidelines: A Clinical Review
8 Osteopathic Family Physician (2015)1, 8-12 Osteopathic Family Physician, Volume 7, No. 1, January/February 2015 The JNC 8 Guidelines: A Clinical Review Gary Rivard, DO; Erik Seth Kramer, DO, MPH; Sean
More information